These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 23944295)

  • 1. The pharmacokinetics and pharmacodynamics of dehydroepiandrosterone during use of an ethinylestradiol- and drospirenone-containing oral contraceptive.
    Zimmerman Y; Coelingh Bennink HJ; Wouters W; Ebes F; Fauser BC
    Eur J Contracept Reprod Health Care; 2013 Dec; 18(6):489-500. PubMed ID: 23944295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Restoring testosterone levels by adding dehydroepiandrosterone to a drospirenone containing combined oral contraceptive: I. Endocrine effects.
    Zimmerman Y; Foidart JM; Pintiaux A; Minon JM; Fauser BC; Cobey K; Coelingh Bennink HJ
    Contraception; 2015 Feb; 91(2):127-33. PubMed ID: 25604900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The bioequivalence of the contraceptive steroids ethinylestradiol and drospirenone is not affected by co-administration of dehydroepiandrosterone.
    Zimmerman Y; Wouters W; Coelingh Bennink HJ
    Eur J Contracept Reprod Health Care; 2013 Jun; 18(3):206-14. PubMed ID: 23550808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Restoring testosterone levels by adding dehydroepiandrosterone to a drospirenone containing combined oral contraceptive: II. Clinical effects.
    Zimmerman Y; Foidart JM; Pintiaux A; Minon JM; Fauser BC; Cobey K; Coelingh Bennink HJ
    Contraception; 2015 Feb; 91(2):134-42. PubMed ID: 25496917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maintaining physiological testosterone levels by adding dehydroepiandrosterone to combined oral contraceptives: I. Endocrine effects.
    Coelingh Bennink HJT; Zimmerman Y; Laan E; Termeer HMM; Appels N; Albert A; Fauser BCJM; Thijssen JHH; van Lunsen RHW
    Contraception; 2017 Nov; 96(5):322-329. PubMed ID: 27393080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pituitary function and DHEA-S in male acne and DHEA-S, prolactin and cortisol before and after oral contraceptive treatment in female acne.
    Palatsi R; Reinilä M; Kivinén S
    Acta Derm Venereol; 1986; 66(3):225-30. PubMed ID: 2426899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maintaining physiologic testosterone levels during combined oral contraceptives by adding dehydroepiandrosterone: II. Effects on sexual function. A phase II randomized, double-blind, placebo-controlled study.
    van Lunsen RHW; Zimmerman Y; Coelingh Bennink HJT; Termeer HMM; Appels N; Fauser BCJM; Laan E
    Contraception; 2018 Jul; 98(1):56-62. PubMed ID: 29490289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of a combined oral contraceptive containing 20 mcg of ethinylestradiol and 3 mg of drospirenone on the blood pressure, renin-angiotensin-aldosterone system, insulin resistance, and androgenic profile of healthy young women.
    Giribela CR; Consolim-Colombo FM; Nisenbaum MG; Moraes TL; Giribela AH; Baracat EC; Melo NR
    Gynecol Endocrinol; 2015; 31(11):912-5. PubMed ID: 26172927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Haemostatic and metabolic impact of estradiol pills and drospirenone-containing ethinylestradiol pills vs. levonorgestrel-containing ethinylestradiol pills: A literature review.
    Lete I; Chabbert-Buffet N; Jamin C; Lello S; Lobo P; Nappi RE; Pintiaux A
    Eur J Contracept Reprod Health Care; 2015; 20(5):329-43. PubMed ID: 26007631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral dehydroepiandrosterone for adrenal androgen replacement: pharmacokinetics and peripheral conversion to androgens and estrogens in young healthy females after dexamethasone suppression.
    Arlt W; Justl HG; Callies F; Reincke M; Hübler D; Oettel M; Ernst M; Schulte HM; Allolio B
    J Clin Endocrinol Metab; 1998 Jun; 83(6):1928-34. PubMed ID: 9626121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome.
    Kriplani A; Periyasamy AJ; Agarwal N; Kulshrestha V; Kumar A; Ammini AC
    Contraception; 2010 Aug; 82(2):139-46. PubMed ID: 20654754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles.
    Gaspard U; Endrikat J; Desager JP; Buicu C; Gerlinger C; Heithecker R
    Contraception; 2004 Apr; 69(4):271-8. PubMed ID: 15033400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of oral contraceptives on androgen levels and their relevance to premenstrual mood and sexual interest: a comparison of two triphasic formulations containing norgestimate and either 35 or 25 microg of ethinyl estradiol.
    Greco T; Graham CA; Bancroft J; Tanner A; Doll HA
    Contraception; 2007 Jul; 76(1):8-17. PubMed ID: 17586130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of combined oral contraceptives containing drospirenone on hypothalamic-pituitary-adrenocortical axis activity and glucocorticoid receptor expression and function in women with polycystic ovary syndrome.
    Macut D; Božić Antić I; Nestorov J; Topalović V; Bjekić Macut J; Panidis D; Kastratović Kotlica B; Papadakis E; Matić G; Vojnović Milutinović D
    Hormones (Athens); 2015; 14(1):109-17. PubMed ID: 25402380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial.
    Koltun W; Lucky AW; Thiboutot D; Niknian M; Sampson-Landers C; Korner P; Marr J
    Contraception; 2008 Apr; 77(4):249-56. PubMed ID: 18342647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of oral contraceptives on markers of hyperandrogenism and SHBG in women with polycystic ovary syndrome.
    De Leo V; Di Sabatino A; Musacchio MC; Morgante G; Scolaro V; Cianci A; Petraglia F
    Contraception; 2010 Sep; 82(3):276-80. PubMed ID: 20705157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of 2 combined oral Contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea.
    van Vloten WA; van Haselen CW; van Zuuren EJ; Gerlinger C; Heithecker R
    Cutis; 2002 Apr; 69(4 Suppl):2-15. PubMed ID: 12096825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of effects of an oral contraceptive containing ethinylestradiol combined with drospirenone on adrenal steroidogenesis in hyperandrogenic women with polycystic ovary syndrome.
    De Leo V; Morgante G; Piomboni P; Musacchio MC; Petraglia F; Cianci A
    Fertil Steril; 2007 Jul; 88(1):113-7. PubMed ID: 17418832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of two combined oral contraceptives containing ethinyl estradiol 30 microg combined with either gestodene or drospirenone on hemostatic parameters, lipid profiles and blood pressure.
    Yildizhan R; Yildizhan B; Adali E; Yoruk P; Birol F; Suer N
    Arch Gynecol Obstet; 2009 Aug; 280(2):255-61. PubMed ID: 19125264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A historical cycle control comparison of two drospirenone-containing combined oral contraceptives: ethinylestradiol 30 μg/drospirenone 3 mg administered in a 21/7 regimen versus ethinylestradiol 20 μg/drospirenone 3 mg administered in a 24/4 regimen.
    Marr J; Gerlinger C; Kunz M
    Eur J Obstet Gynecol Reprod Biol; 2012 May; 162(1):91-5. PubMed ID: 22391750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.